OR2L13
Olfactory receptor 2L13
Also known as: OR2L14, OR2LD_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q8N349
- Gene
- OR2L13
- Ensembl
- ENSG00000196071
- Chromosome
- 1
- Canonical length
- 312 aa
- Protein class
- G-protein coupled receptors, Predicted membrane proteins
OverviewNCBI Gene
Olfactory receptors interact with odorant molecules in the nose, to initiate a neuronal response that triggers the perception of a smell. The olfactory receptor proteins are members of a large family of G-protein-coupled receptors (GPCR) arising from single coding-exon genes. Olfactory receptors share a 7-transmembrane domain structure with many neurotransmitter and hormone receptors and are responsible for the recognition and G protein-mediated transduction of odorant signals. The olfactory receptor gene family is the largest in the genome. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
312 residues, UniProt reviewed canonical sequence.
>Q8N349|OR2L13
1 MEKWNHTSND FILLGLLPPN QTGIFLLCLI ILIFFLASVG NSAMIHLIHV DPRLHTPMYF
61 LLSQLSLMDL MYISTTVPKM AYNFLSGQKG ISFLGCGVQS FFFLTMACSE GLLLTSMAYD
121 RYLAICHSLY YPIRMSKMMC VKMIGGSWTL GSINSLAHTV FALHIPYCRS RAIDHFFCDV
181 PAMLLLACTD TWVYEYMVFV STSLFLLFPF IGITSSCGRV LFAVYHMHSK EGRKKAFTTI
241 STHLTVVIFY YAPFVYTYLR PRNLRSPAED KILAVFYTIL TPMLNPIIYS LRNKEVLGAM
301 RRVFGIFSFL KELocalizationUniProt · AlphaFold · HPA
Whether an antibody against OR2L13 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 7
- Mean surface accessibility (rSASA)
- 0.27
- Highest tissue expression
- 5.7 nTPM
Expression across tissuesHPA
Tissue
- spinal cord: 5.7 nTPM
- cerebral cortex: 3.4 nTPM
- hypothalamus: 3.2 nTPM
- midbrain: 3.2 nTPM
- hippocampal formation: 2.5 nTPM
- basal ganglia: 2.2 nTPM
Single-cell type
- oligodendrocytes: 6.3 nCPM
- hematopoietic stem cells: 4.4 nCPM
- late primary spermatocytes: 4.1 nCPM
- retinal ganglion cells: 3.9 nCPM
- other brain neurons: 3.7 nCPM
- brain inhibitory neurons: 3.4 nCPM
Immune cell
- basophil: 0.8 nTPM
- naive CD8 T-cell: 0.3 nTPM
- memory B-cell: 0.2 nTPM
- naive B-cell: 0.1 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
Brain region
- white matter: 11 nTPM
- pons: 8.6 nTPM
- cerebral cortex: 8.5 nTPM
- medulla oblongata: 7.7 nTPM
- spinal cord: 6.2 nTPM
- hypothalamus: 6 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.58
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.24
- DepMap mean gene effect
- 0.01
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads OR2L13 as an antibody target. Whether an autoantibody or antibody against OR2L13 could matter depends on whether native OR2L13 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
OR2L13 is annotated at the cell surface, where native OR2L13 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label OR2L13 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...